Dolutegravir Resistance in Malawi’s National HIV Treatment Program
Joep J. van Oosterhout, Chifundo Chipungu, Lyse Nkhoma, Hope Kanise, Mina C. Hosseinipour, Jean Babtiste Sagno, Katherine Simon, Carrie M. Cox, Risa M. Hoffman, Kim Steegen, Bilaal W Matola, Sam Phiri, Andreas Jahn, Rose Nyirenda, Tom Heller
Abstract
Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020-September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity.
Topics & Concepts
DolutegravirMedicineHIV drug resistanceHuman immunodeficiency virus (HIV)VirologyDrug resistanceAntiretroviral therapyAntiretroviral drugViral loadMicrobiologyBiologyHIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV Research and Treatment